26 studies found for:    CAL101
Show Display Options
Rank Status Study
1 Recruiting Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
Conditions: Indolent Non-Hodgkin's Lymphoma;   Follicular Lymphoma;   Small Lymphocytic Lymphoma;   Marginal Zone Lymphoma
Intervention: Drug: Idelalisib
2 Active, not recruiting Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Indolent Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Mantle Cell Lymphoma
Interventions: Drug: Idelalisib;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Ofatumumab;   Drug: Fludarabine;   Drug: Everolimus;   Drug: Bortezomib;   Drug: Chlorambucil;   Drug: Lenalidomide
3 Active, not recruiting Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: Idelalisib
4 Active, not recruiting A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Idelalisib;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Placebo to match idelalisib
5 Recruiting A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Idelalisib;   Drug: Ofatumumab
6 Active, not recruiting
Has Results
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
Conditions: Follicular Lymphoma;   Small Lymphocytic Lymphoma;   Lymphoplasmacytic Lymphoma;   Marginal Zone Lymphoma
Intervention: Drug: Idelalisib
7 Active, not recruiting
Has Results
A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Idelalisib;   Drug: Rituximab;   Drug: Placebo to match idelalisib
8 Active, not recruiting Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Idelalisib;   Drug: Idelalisib placebo
9 Active, not recruiting A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma (SLL)
Interventions: Drug: Idelalisib;   Drug: Rituximab
10 Active, not recruiting Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Condition: Indolent Non-Hodgkin's Lymphomas
Interventions: Drug: Idelalisib;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Placebo to match idelalisib
11 Completed Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber
Condition: Allergic Rhinitis
Interventions: Drug: CAL-101;   Drug: Placebo
12 Recruiting Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Condition: Indolent Non-Hodgkin's Lymphomas
Interventions: Drug: Idelalisib;   Drug: Rituximab;   Drug: Placebo to match idelalisib
13 Active, not recruiting A Phase 2 of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies
Conditions: Chronic Lymphocytic Leukemia;   Mantle Cell Lymphoma;   Diffuse Large B-cell Lymphoma;   Indolent Non-Hodgkin's Lymphoma
Interventions: Drug: GS-9973;   Drug: Idelalisib
14 Enrolling by invitation An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study
Conditions: Chronic Lymphocytic Leukemia;   Lymphoma, Non-Hodgkin
Intervention: Drug: Idelalisib
15 Active, not recruiting Efficacy and Safety of Idelalisib (GS-1101; CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Idelalisib;   Drug: Ofatumumab
16 Recruiting Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Adults With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas or Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Indolent Non-Hodgkin Lymphoma;   Follicular Lymphoma;   Small Lymphocytic Lymphoma;   Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia);   Marginal Zone Lymphoma
Intervention: Drug: Idelalisib
17 Withdrawn A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: GS-1101
18 Active, not recruiting Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Idelalisib;   Drug: Bendamustine;   Drug: Rituximab;   Drug: Placebo to match idelalisib
19 Not yet recruiting Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Idelalisib;   Drug: Chlorambucil;   Drug: Obinutuzumab
20 Recruiting Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
Condition: B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion
Interventions: Drug: Idelalisib;   Drug: Rituximab

   Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results    Last Page
Indicates status has not been verified in more than two years